Crucell Announces PER.C6® Licensing Agreement with Acambis
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Acambis plc (London Stock Exchange: ACM) today announced the signing of a research license agreement for PER.C6®. The license agreement allows Acambis to use Crucell’s PER.C6® technology for an undisclosed vaccine candidate. Financial details of the agreement were not disclosed.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.